Årdal, C., K. Outterson, S.J. Hoffman, A. Ghafur, M. Sharland, N. Ranganathan, et al. 2016. International cooperation to improve access to and sustain effectiveness of antimicrobials. The Lancet 387 (10015): 296–307.
Asenso-Boadi, F., T.J. Peters, and J. Coast. 2008. Exploring differences in empirical time preference rates for health: An application of meta-regression. Health Economics 17: 235–248.
Brogan, D.M., and E. Mossialos. 2016. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline. Social Science & Medicine 151: 167–172.
Coast, J., and R.D. Smith. 2015. Distributional considerations in economic responses to antimicrobial resistance. Public Health Ethics 8 (3): 225–237.
Coast, J., R.D. Smith, and M.R. Millar. 1996. Superbugs: Should antimicrobial resistance be included as a cost in economic evaluation? Health Economics 5: 217–226.
———. 1998. An economic perspective on policy to reduce antimicrobial resistance. Social Science and Medicine 46 (1): 29–38.
Coast, J., R.D. Smith, P. Wilton, A.M. Karcher, and M.R. Millar. 2002. Superbugs II: How should economic evaluation be conducted for interventions which aim to reduce antimicrobial resistance? Health Economics 11 (7).
Coast, J., R.D. Smith, and M.R. Millar. 2006. Disentangling value: Assessing the benefits of containing antimicrobial resistance. In The economics of infectious disease, ed. J.A. Roberts, 201–214. Oxford: Oxford University Press. (Reprinted from: In File).
Cormican, M., and A. Vellinga. 2012. Existing classes of antibiotics are probably the best we will ever have. British Medical Journal 344: e3369.
Courvalin, P. 2008. Predictable and unpredictable evolution of antibiotic resistance. Journal of Internal Medicine 264 (1): 4–16.
Dar, O.A., R. Hasan, J. Schlundt, S. Harbarth, G. Caleo, F.K. Dar, et al. 2016. Exploring the evidence base for national and regional policy interventions to combat resistance. The Lancet 387 (10015): 285–295.
Doshi, P. 2015. Speeding new antibiotics to market: A fake fix? BMJ: British Medical Journal 350: h1453.
GlaxoSmithKline. 2013. GlaxoSmithKline awarded up to $200 million by U.S. Government to develop new antibiotics. Middlesex: GlaxoSmithKline.
Goossens, H., D. Guillemot, M. Ferech, B. Schlemmer, M. Costers, M. Van Breda, L.J. Baker, et al. 2006. National campaigns to improve antibiotic use. European Journal of Clincal Pharmacology 62: 373–379.
Guiness, L., and V. Wiseman. 2011. Introduction to health economics. 2nd ed. Maidenhead: McGraw-Hill Education.
Hanefeld, J., M. Khan, G. Tomson, and R. Smith. 2017. Trade is central to achieving the sustainable development goals: A case study of antimicrobial resistance. BMJ 358: j3505.
Hardin, G. 1968. The tragedy of the commons. Science 162 (3859): 1243–1248.
Hatch, O. 2015. Promise for antibiotics and therapeutics for health act or the PATH act. In. www.congress.gov/bill/114th-congress/senate-bill/185?q=%7B%22search%22%3A%5B%22s.185%22%5D%7D.
Hoffman, S.J., K. Outterson, J.-A. Røttingen, O. Cars, C. Clift, Z. Rizvi, et al. 2015a. An international legal framework to address antimicrobial resistance. Bulletin of the World Health Organization 93 (2): 66–66.
Hoffman, S.J., J.-A. Røttingen, and J. Frenk. 2015b. Assessing proposals for new global health treaties: An analytic framework. American Journal of Public Health 105 (8): 1523–1530.
Huttner, B., H. Goossens, T. Verheij, and S. Harbarth. 2010. Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high- income countries. Lancet Infectious Diseases 10: 17–31.
Keppler, H. 2013. The untold AIDS story: How access to antiretroviral drugs was obstruced in Africa.
Kesselheim, A.S., and K. Outterson. 2010. Fighting antibiotic resistance: Marrying new financial incentives to meeting public health goals. Health Affairs 29 (9): 1689–1696.
Kolmos, H.J., and P. Little. 1999. Should general practitioners perform diagnostic tests on patients before prescribing antibiotics? British Medical Journal 318: 799–802.
Laxminarayan, R., I.W.H. Parry, D.L. Smith, and E.Y. Klein. 2010. Should new antimalarial drugs be subsidized? Journal of Health Economics 29: 445–456.
Laxminarayan, R., P. Matsoso, S. Pant, C. Brower, J.-A. Røttingen, K. Klugman, and S. Davies. 2016. Access to effective antimicrobials: A worldwide challenge. The Lancet 387 (10014): 168–175.
Medical Research Council. 2014. Tackling AMR theme 2: Accelerating therapeutic and diagnostics development EOI. In. www.mrc.ac.uk/funding/browse/tackling-amr-theme-2-accelerating-therapeutic-and-diagnostics-development-eoi.
Mendelson, M., J.-A. Røttingen, U. Gopinathan, D.H. Hamer, H. Wertheim, B. Basnyat, et al. 2016. Maximising access to achieve appropriate human antimicrobial use in low-income and middle-income countries. The Lancet 387 (10014): 188–198.
Molzon, J.A., A. Giaquinto, L. Lindstrom, T. Tominaga, M. Ward, P. Doerr, et al. 2011. The value and benefits of the international conference on harmonisation to drug regulatory authorities: Advancing harmonization for better public health. Clinical Pharmacology & Therapeutics 89 (4): 503–512.
Nesta. 2014. The challenge: Reduce the use of antibiotics. In. https://longitudeprize.org/challenge.
O’Neill, J. 2014. Review on antimicrobial resistance. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. London: HM Government; Wellcome Trust.
Olsen, J.A., and J. Richardson. 2013. Preferences for the normative basis of health care priority setting: Some evidence from two countries. Health Economics 22 (4): 480–485.
Oppong, R., M. Jit, R.D. Smith, C.C. Butler, H. Melbye, S. Molstad, and J. Coast. 2013. Cost-effectiveness of point-of-care C-reactive protein testing to inform antibiotic prescribing decisions. British Journal of General Practice 63 (612): e465–e471.
Outterson, K. 2014. New business models for sustainable antibiotics. London: Chatham House.
Outterson, K., J.H. Powers, G.W. Daniel, and M.B. McClellan. 2015. Repairing the broken market for antibiotic innovation. Health Affairs 34 (2): 277–285.
Review on antimicrobial resistance. 2015a. Tackling a global health crisis: Initial steps.
———. 2015b. Securing new drugs for future generations: The pipeline of antibiotics.
Rice, L.B. 2011. Rapid diagnostics and appropriate antibiotic use. Clinical Infectious Diseases 52 (Suppl 4): S357–S360.
Richardson, J., and J. McKie. 2007. Economics, political philosophy and ethics: The role of public preferences in health care decision–making. In Principles of health care ethics, 2nd ed., 569–576.
Smith, R. 2015. Antimicrobial resistance is a social problem requiring a social solution. BMJ: British Medical Journal 350: h1453.
Smith, R.D., and J. Coast. 1998. Controlling antimicrobial resistance: A proposed transferable permit market. Health Policy 43: 219–232.
———. 2002. Antimicrobial resistance: a global response. Bulletin of the World Health Organization 80: 126–133.
———. 2003. Antimicrobial drug resistance. In Global public goods for health: A health economic and public health perspective, ed. R.D. Smith, R. Beaglehole, D. Woodward, and N. Drager. Oxford: Oxford University Press.
Smith, R., and J. Coast. 2013. The true cost of antimicrobial resistance. BMJ 346 (f1493): 1–5.
Smith, R.D., C. Carlos, and O. Cecilia. 2009. Trade, TRIPS, and pharmaceuticals. Lancet 373 (9664): 684–691.
Trouiller, P., P. Olliaro, E. Torreele, J. Orbinski, R. Laing, and N. Ford. 2002. Drug development for neglected diseases: A deficient market and a public-health policy failure. The Lancet 359 (9324): 2188–2194.
Walls, H.L., and G. Ooms. 2017. Innovative use of the law to address complex global health problems: Comment on the legal strength of international health instruments-what it brings to global health governance? International Journal of Health Policy Management 6.
Wilton, P., R.D. Smith, J. Coast, and M.R. Millar. 2002. Strategies to contain the emergence of antimicrobial resistance: A systematic review of effectiveness and cost- effectiveness. Journal of Health Services Research and Policy 7: 111–117.
Wise, J. 2015. Report calls for $2 bn global fund to kickstart antibiotic development. BMJ: British Medical Journal 350: h2635.
Woodward, D., and R.D. Smith. 2003. Global public goods for health: Concepts and issues. In Global public goods for health: A health economic and public health perspective, ed. R.D. Smith, R. Beaglehole, D. Woodward, and N. Drager. Oxford: Oxford University Press.
Woolhouse, M., and J. Farrar. 2014. Policy: An intergovernmental panel on antimicrobial resistance. Nature 509 (7502): 555–557.
World Health Organization. 2015. Tracking universal health coverage: First global monitoring report. Geneva: World Health Organization.
Yamabhai, I., and R.D. Smith. 2015. To what extent are pharmaceutical prices determined by patents? A case study of oncology medicines in Thailand. Journal of Intellectual Property Rights 20: 89–95.